Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
07-09 April, 2026
Health 2.0 ConferenceHealth 2.0 Conference
Not Confirmed
Not Confirmed
07-09 April, 2026
Not Confirmed
Not Confirmed
09-12 April, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
IPhEB Russia
Not Confirmed
Contact SupplierIPhEB Russia
Industry Trade Show
Not Confirmed
07-09 April, 2026
Health 2.0 ConferenceHealth 2.0 Conference
Industry Trade Show
Not Confirmed
07-09 April, 2026
Industry Trade Show
Not Confirmed
09-12 April, 2026
Digital content
NEWS #PharmaBuzz
21 Mar 2026
// BIOSPACE
19 Mar 2026
// BIOSPACE
https://www.biospace.com/business/gossamer-nearly-halves-workforce-in-savings-push-after-late-stage-hypertension-fail
17 Mar 2026
// BUSSINESSWIRE
https://www.businesswire.com/news/home/20260317488156/en/Gossamer-Bio-Announces-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Corporate-Update
23 Feb 2026
// FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/gossamer-bio-fails-phase-3-pulmonary-arterial-hypertension-trial-tries-thread-path-market
08 Jan 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260108468807/en/Gossamer-Bio-Announces-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635c4
09 Dec 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251209606832/en/Gossamer-Bio-Announces-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635c4
Drugs in Development
Details:
Respira is developing RT234 (vardenafil inhalation powder) as the first as-needed (PRN) therapy for use in pulmonary hypertension (PH).
Lead Product(s): Vardenafil Hydrochloride
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: RT234
Study Phase: Phase IIProduct Type: Miscellaneous
Recipient: Respira Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 25, 2025
Lead Product(s) : Vardenafil Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Recipient : Respira Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Respira Therapeutics Grants Gossamer Option to Acquire It from Samsara BioCapital
Details : Respira is developing RT234 (vardenafil inhalation powder) as the first as-needed (PRN) therapy for use in pulmonary hypertension (PH).
Product Name : RT234
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 25, 2025
Details:
Gossamer Bio continues developing GB002 (seralutinib), an inhaled inhibitor for pulmonary hypertension, while Chiesi will commercialize it outside the U.S.
Lead Product(s): Seralutinib
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Chiesi Group
Deal Size: $326.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration May 06, 2024
Lead Product(s) : Seralutinib
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Chiesi Group
Deal Size : $326.0 million
Deal Type : Collaboration
Gossamer Bio and Chiesi Group Collaborate to Develop Seralutinib for PAH and PH-ILD
Details : Gossamer Bio continues developing GB002 (seralutinib), an inhaled inhibitor for pulmonary hypertension, while Chiesi will commercialize it outside the U.S.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 06, 2024
Details:
Gossamer intends to use the net proceeds to fund the ongoing development and commercialization of GB002 (seralutinib), a tyrosine kinase inhibitor targeting PDGFRα/β, CSF1R, and c-KIT, for the treatment of pulmonary arterial hypertension (PAH).
Lead Product(s): Seralutinib
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: New Enterprise Associates
Deal Size: $212.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement July 20, 2023
Lead Product(s) : Seralutinib
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : New Enterprise Associates
Deal Size : $212.0 million
Deal Type : Private Placement
Gossamer Bio Announces $212 Million Private Placement Financing
Details : Gossamer intends to use the net proceeds to fund the ongoing development and commercialization of GB002 (seralutinib), a tyrosine kinase inhibitor targeting PDGFRα/β, CSF1R, and c-KIT, for the treatment of pulmonary arterial hypertension (PAH).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 20, 2023
Details:
The FDA has now placed a clinical hold on all trials of GB5121, which was being tested for primary central nervous system lymphoma. Now, all work related to GB5121 has been discontinued and the ongoing studies shelved.
Lead Product(s): GB5121
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 03, 2023
Lead Product(s) : GB5121
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Gossamer Halts Work on BTK Inhibitor After 2 Patient Deaths
Details : The FDA has now placed a clinical hold on all trials of GB5121, which was being tested for primary central nervous system lymphoma. Now, all work related to GB5121 has been discontinued and the ongoing studies shelved.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 03, 2023
Details:
The efficacy results generated with GB002 (seralutinib) in the context of a favorable safety and tolerability profile highlight compelling potential differentiation for seralutinib as an anti-proliferative, anti-inflammatory, and anti-fibrotic therapeutic candidate.
Lead Product(s): Seralutinib
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 06, 2022
Lead Product(s) : Seralutinib
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Gossamer Bio Announces Seralutinib Meets Primary Endpoint in Phase 2 TORREY Study in PAH
Details : The efficacy results generated with GB002 (seralutinib) in the context of a favorable safety and tolerability profile highlight compelling potential differentiation for seralutinib as an anti-proliferative, anti-inflammatory, and anti-fibrotic therapeuti...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 06, 2022
Details:
Gossamer intends to use the net proceeds from the proposed financing to fund research and development of its other product candidates and development programs and for working capital and general corporate purposes.
Lead Product(s): Seralutinib
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: EcoR1 Capital
Deal Size: $120.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement July 13, 2022
Lead Product(s) : Seralutinib
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : EcoR1 Capital
Deal Size : $120.0 million
Deal Type : Private Placement
Gossamer Bio Announces $120 Million Private Placement Financing
Details : Gossamer intends to use the net proceeds from the proposed financing to fund research and development of its other product candidates and development programs and for working capital and general corporate purposes.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 13, 2022
Details:
Seralutinib (GB002) is an inhaled PDGFRα and PDGFRβ inhibitor. The primary objective for this trial is to determine the effect of GB002 on improving pulmonary hemodynamics in subjects with WHO Group 1 PAH who are Functional Class II and III.
Lead Product(s): Seralutinib
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 09, 2022
Lead Product(s) : Seralutinib
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Seralutinib (GB002) is an inhaled PDGFRα and PDGFRβ inhibitor. The primary objective for this trial is to determine the effect of GB002 on improving pulmonary hemodynamics in subjects with WHO Group 1 PAH who are Functional Class II and III.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 09, 2022
Details:
Neither statistically significant nor clinically meaningful differences were observed for primary endpoint and secondary endpoints, including histologic and mucosal healing endpoints, for either GB004 treatment group relative to placebo at week 12.
Lead Product(s): GB004
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 25, 2022
Lead Product(s) : GB004
Therapeutic Area : Immunology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Neither statistically significant nor clinically meaningful differences were observed for primary endpoint and secondary endpoints, including histologic and mucosal healing endpoints, for either GB004 treatment group relative to placebo at week 12.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 25, 2022
Details:
GB5121 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Central Nervous System Lymphoma.
Lead Product(s): GB5121
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 16, 2022
GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma
Details : GB5121 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Central Nervous System Lymphoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 16, 2022
Details:
Seralutinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pulmonary Arterial Hypertension.
Lead Product(s): Seralutinib
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 25, 2021
Lead Product(s) : Seralutinib
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
Details : Seralutinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pulmonary Arterial Hypertension.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 25, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
